Targeted chemo pumped directly to liver shows promise in tough cancer
NCT ID NCT03364530
Summary
This study is testing a new way to deliver chemotherapy for a rare and hard-to-treat liver cancer called cholangiocarcinoma. It is for patients whose cancer has not spread beyond the liver but cannot be surgically removed, and whose cancer has worsened after standard first-line treatment. Doctors deliver the drugs (gemcitabine and oxaliplatin) directly into the artery that feeds the liver tumor, aiming to shrink the cancer more effectively while potentially reducing side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA NON-RESECTABLE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amiens University Hospital
RECRUITINGAmiens, France
Contact
-
Angers University Hospital
RECRUITINGAngers, France
Contact
-
Bordeaux University Hospital
RECRUITINGBordeaux, France
Contact
-
Centre Georges François Leclerc
RECRUITINGDijon, France
Contact
-
Hôpital Européen Georges Pompidou
RECRUITINGParis, France
Contact
-
Institut Gustave Roussy
RECRUITINGVillejuif, France
Contact
-
Uhmontpellier
RECRUITINGMontpellier, 34295, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.